跳至主要内容
临床试验/NCT03208127
NCT03208127终止4 期

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2017年11月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
33
试验地点
1
主要终点
Number of Participants With Undetectable Hepatitis C Virus (HCV) Viral RNA

研究概览

简要总结

This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

详细描述

Patients will be selected based on diminished likelihood of receiving a liver from the waitlist within a period during which they would be likely to succumb to severe comorbidities. This will be determined in part through use of a patient's Model of End Stage Liver Disease (MELD) score, listing status, and clinical judgment. To ensure maximal benefit for the recipient, only high quality donor livers will be accepted.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recipient is Age ≥ 18 years
  • Met Massachusetts General Hospital (MGH) transplant center criteria, listed for liver transplant
  • HCV naïve
  • Able to sign informed consent

排除标准

  • Pregnant or nursing (lactating) women
  • Human immunodeficiency virus (HIV) positivity
  • Need for dual organ transplant
  • Any contra-indication to liver transplantation per center protocol

研究组 & 干预措施

Treatment with Direct Acting Antiviral (DAA) Fixed Dose Combination

Experimental

12 weeks of HCV treatment with medically appropriate direct acting antiviral

干预措施: Treatment with Direct Acting Antiviral tablet (Drug)

结局指标

主要结局

Number of Participants With Undetectable Hepatitis C Virus (HCV) Viral RNA

时间窗: 12 weeks post treatment

Number of dosed subjects with negative HCV viral RNA at 12 weeks after the last dose of treatment.

次要结局

  • Number of Participants With Treatment Emergent Adverse Events and Out of Range Lab Values(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Raymond Chung

Director of Hepatology

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验